Evommune, Inc. (EVMN)

Evommune Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023
Net Income	-64.76	-66.81	-34.05
Depreciation & Amortization	1.44	1.29	1
Loss (Gain) From Sale of Investments	-1.44	-1.82	-1.75
Stock-Based Compensation	2	1.72	1.48
Change in Accounts Payable	-14.12	6.51	0.13
Change in Unearned Revenue	-3	-	3
Change in Other Net Operating Assets	-6.03	0.92	0.22
Operating Cash Flow	-94.85	-58.2	-29.97
Capital Expenditures	-	-0.09	-0.12
Investment in Securities	7.83	-3.91	-48.32
Investing Cash Flow	7.83	-3.99	-48.43
Long-Term Debt Repaid	-	-0.42	-0.23
Net Debt Issued (Repaid)	-0.56	-0.42	-0.23
Issuance of Common Stock	0.02	0.01	0.01
Financing Cash Flow	113.78	49.42	63.75
Net Cash Flow	26.76	-12.77	-14.65
Free Cash Flow	-94.85	-58.28	-30.09
Free Cash Flow Margin	-3161.53%	-832.61%	-601.76%
Free Cash Flow Per Share	-7.37	-4.54	-2.82
Cash Interest Paid	0.02	0.03	0.06
Levered Free Cash Flow	-	-20.82	-
Unlevered Free Cash Flow	-	-20.8	-
Change in Working Capital	-23.15	7.42	3.34

Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q